---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-120146"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:32:13.238681+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer

## Summary
- Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.
- Trial enrolls up to 45 colorectal cancer patients with ctDNA positivity after curative-intent therapy.
- Phase 2a expected to start first half 2026; led by Dr. Paula Pohlmann of MD Anderson Cancer Center.
- Decision based on positive Phase 1 safety data and durable anti-tumor effects.
- TTX-MC138 targets metastatic disease; aims to intervene in minimal residual disease setting.

## SEC filing metadata
- accession: 0001104659-25-120146
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925120146/0001104659-25-120146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925120146/tm2533194d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-120146
- JSON: https://secwatch.observer/filing/0001104659-25-120146.json
- Plain text: https://secwatch.observer/filing/0001104659-25-120146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.